63 related articles for article (PubMed ID: 1518726)
1. Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.
Petros WP; Rodman JH; Relling MV; Christensen M; Pui CH; Rivera GK; Evans WE
Pharmacotherapy; 1992; 12(4):273-7. PubMed ID: 1518726
[TBL] [Abstract][Full Text] [Related]
2. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
Evans WE; Rodman JH; Relling MV; Petros WP; Stewart CF; Pui CH; Rivera GK
J Pharmacol Exp Ther; 1992 Jan; 260(1):71-7. PubMed ID: 1731053
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
[TBL] [Abstract][Full Text] [Related]
4. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
Yang L; Panetta JC; Cai X; Yang W; Pei D; Cheng C; Kornegay N; Pui CH; Relling MV
J Clin Oncol; 2008 Apr; 26(12):1932-9. PubMed ID: 18421047
[TBL] [Abstract][Full Text] [Related]
5. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients.
Stewart CF; Fleming RA; Arbuck SG; Evans WE
Cancer Res; 1990 Nov; 50(21):6854-6. PubMed ID: 2208152
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of serum protein binding of felodipine.
Valle M; Esteban M; Rodríguez-Sasiaín JM; Calvo R; Aguirre C
Res Commun Mol Pathol Pharmacol; 1996 Oct; 94(1):73-88. PubMed ID: 8948016
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
[TBL] [Abstract][Full Text] [Related]
11. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.
Rodman JH; Furman WL; Sunderland M; Rivera G; Evans WE
J Clin Oncol; 1993 Feb; 11(2):287-93. PubMed ID: 8426206
[TBL] [Abstract][Full Text] [Related]
12. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
13. Increased teniposide clearance with concomitant anticonvulsant therapy.
Baker DK; Relling MV; Pui CH; Christensen ML; Evans WE; Rodman JH
J Clin Oncol; 1992 Feb; 10(2):311-5. PubMed ID: 1732431
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia.
Rivera GK; Evans WE
Semin Oncol; 1992 Apr; 19(2 Suppl 6):51-8. PubMed ID: 1411639
[TBL] [Abstract][Full Text] [Related]
15. [Allergic reactions to teniposide (VM-26) in children with neoplasms].
Wysocki M; Nowaczyk-Michalak A; Pilecki O
Wiad Lek; 1992 Feb; 45(3-4):91-3. PubMed ID: 1413803
[TBL] [Abstract][Full Text] [Related]
16. Quantitative contribution of endogenous compounds and hypoalbuminemia in reducing the binding of furosemide in the plasma of newborn infants.
Viani A; Pacifici GM
Dev Pharmacol Ther; 1992; 18(1-2):39-43. PubMed ID: 1483361
[TBL] [Abstract][Full Text] [Related]
17. Teniposide for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 1992 Nov; 34(883):105-6. PubMed ID: 1435505
[No Abstract] [Full Text] [Related]
18. Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.
Imbs DC; Paludetto MN; Négrier S; Powell H; Lafont T; White-Koning M; Chatelut E; Thomas F
Invest New Drugs; 2016 Feb; 34(1):41-8. PubMed ID: 26572909
[TBL] [Abstract][Full Text] [Related]
19. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia.
McLeod HL; Baker DK; Pui CH; Rodman JH
Cancer Chemother Pharmacol; 1991; 29(2):150-4. PubMed ID: 1760858
[TBL] [Abstract][Full Text] [Related]
20. Low levels of serum transport proteins indicate catabolic protein status during induction therapy for acute lymphoblastic leukemia.
Koskelo EK; Saarinen UM; Siimes MA
Pediatr Hematol Oncol; 1991; 8(1):53-9. PubMed ID: 1903045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
